CAPR Quote, Financials, Valuation and Earnings

Arcturus Therapeutics Holdings, Inc. has a net margin of -63.94% compared to Capricor Therapeutics, Inc.'s net margin of -95.02%. Capricor Therapeutics, Inc.'s return on equity of -77.32% beat Arcturus Therapeutics Holdings, Inc.'s return on equity of -27.98%.

Capricor Therapeutics, Inc. has a consensus price target of $20.70, signalling downside risk potential of -30.91%. On the other hand Arcturus Therapeutics Holdings, Inc. has an analysts' consensus of $35.50 which suggests that it could grow by 438.7%. Given that Arcturus Therapeutics Holdings, Inc. has higher upside potential than Capricor Therapeutics, Inc., analysts believe Arcturus Therapeutics Holdings, Inc. is more attractive than Capricor Therapeutics, Inc..

Capricor Therapeutics, Inc. has a beta of 0.614, which suggesting that the stock is 38.632% less volatile than S&P 500. In comparison Arcturus Therapeutics Holdings, Inc. has a beta of 2.102, suggesting its more volatile than the S&P 500 by 110.246%.

Capricor Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcturus Therapeutics Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics, Inc. pays -- of its earnings as a dividend. Arcturus Therapeutics Holdings, Inc. pays out -- of its earnings as a dividend.

Capricor Therapeutics, Inc. quarterly revenues are --, which are smaller than Arcturus Therapeutics Holdings, Inc. quarterly revenues of $14.2M. Capricor Therapeutics, Inc.'s net income of -$24.6M is lower than Arcturus Therapeutics Holdings, Inc.'s net income of -$13.4M. Notably, Capricor Therapeutics, Inc.'s price-to-earnings ratio is -- while Arcturus Therapeutics Holdings, Inc.'s PE ratio is 8.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics, Inc. is 122.18x versus 2.10x for Arcturus Therapeutics Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Armata Pharmaceuticals, Inc. has a net margin of -63.94% compared to Capricor Therapeutics, Inc.'s net margin of -2301.55%. Capricor Therapeutics, Inc.'s return on equity of -77.32% beat Armata Pharmaceuticals, Inc.'s return on equity of --.

Capricor Therapeutics, Inc. has a consensus price target of $20.70, signalling downside risk potential of -30.91%. On the other hand Armata Pharmaceuticals, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 50.25%. Given that Armata Pharmaceuticals, Inc. has higher upside potential than Capricor Therapeutics, Inc., analysts believe Armata Pharmaceuticals, Inc. is more attractive than Capricor Therapeutics, Inc..

Capricor Therapeutics, Inc. has a beta of 0.614, which suggesting that the stock is 38.632% less volatile than S&P 500. In comparison Armata Pharmaceuticals, Inc. has a beta of 1.240, suggesting its more volatile than the S&P 500 by 23.97%.

Capricor Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics, Inc. pays -- of its earnings as a dividend. Armata Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Capricor Therapeutics, Inc. quarterly revenues are --, which are smaller than Armata Pharmaceuticals, Inc. quarterly revenues of $1.2M. Capricor Therapeutics, Inc.'s net income of -$24.6M is higher than Armata Pharmaceuticals, Inc.'s net income of -$26.7M. Notably, Capricor Therapeutics, Inc.'s price-to-earnings ratio is -- while Armata Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics, Inc. is 122.18x versus 49.69x for Armata Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Inovio Pharmaceuticals, Inc. has a net margin of -63.94% compared to Capricor Therapeutics, Inc.'s net margin of -30140.49%. Capricor Therapeutics, Inc.'s return on equity of -77.32% beat Inovio Pharmaceuticals, Inc.'s return on equity of -252.43%.

Capricor Therapeutics, Inc. has a consensus price target of $20.70, signalling downside risk potential of -30.91%. On the other hand Inovio Pharmaceuticals, Inc. has an analysts' consensus of $7.63 which suggests that it could grow by 277.89%. Given that Inovio Pharmaceuticals, Inc. has higher upside potential than Capricor Therapeutics, Inc., analysts believe Inovio Pharmaceuticals, Inc. is more attractive than Capricor Therapeutics, Inc..

Capricor Therapeutics, Inc. has a beta of 0.614, which suggesting that the stock is 38.632% less volatile than S&P 500. In comparison Inovio Pharmaceuticals, Inc. has a beta of 1.544, suggesting its more volatile than the S&P 500 by 54.377%.

Capricor Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics, Inc. pays -- of its earnings as a dividend. Inovio Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Capricor Therapeutics, Inc. quarterly revenues are --, which are smaller than Inovio Pharmaceuticals, Inc. quarterly revenues of --. Capricor Therapeutics, Inc.'s net income of -$24.6M is higher than Inovio Pharmaceuticals, Inc.'s net income of -$45.5M. Notably, Capricor Therapeutics, Inc.'s price-to-earnings ratio is -- while Inovio Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics, Inc. is 122.18x versus 448.96x for Inovio Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -63.94% compared to Capricor Therapeutics, Inc.'s net margin of 13.19%. Capricor Therapeutics, Inc.'s return on equity of -77.32% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

Capricor Therapeutics, Inc. has a consensus price target of $20.70, signalling downside risk potential of -30.91%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 539.54%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Capricor Therapeutics, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Capricor Therapeutics, Inc..

Capricor Therapeutics, Inc. has a beta of 0.614, which suggesting that the stock is 38.632% less volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.

Capricor Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Capricor Therapeutics, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Capricor Therapeutics, Inc. quarterly revenues are --, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Capricor Therapeutics, Inc.'s net income of -$24.6M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Capricor Therapeutics, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 24.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Capricor Therapeutics, Inc. is 122.18x versus 2.19x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.